Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

906
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
906
Analgesia and Pain Management01:25

Analgesia and Pain Management

1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

4.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.0K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

841
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
841
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in physician task load are associated with gender variance in physician well-being metrics.

BMJ quality & safety·2026
Same author

Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial.

Addiction (Abingdon, England)·2026
Same author

Navigating an unpredictable supply: lived experiences of xylazine exposure among people who use drugs.

Harm reduction journal·2026
Same author

Ensuring continuous buprenorphine access: A multi-component quality improvement initiative in a university-affiliated clinic and outpatient pharmacy.

Journal of the American Pharmacists Association : JAPhA·2026
Same author

Cannabis Use among People Receiving Maintenance Hemodialysis with Chronic Pain.

Kidney360·2026
Same author

A tailored pain self-management intervention for patients with cirrhosis is acceptable and improves pain control.

Hepatology communications·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

2.8K

Barriers to Buprenorphine Initiation in Patients Using Fentanyl.

Sarah S Kawasaki1, Jane M Liebschutz2,3, Cristina Murray-Krezan2,4

  • 1Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.

JAMA Network Open
|January 6, 2026
PubMed
Summary
This summary is machine-generated.

Clinicians frequently encounter difficulties initiating buprenorphine (BUP) treatment for patients using fentanyl, often leading to precipitated withdrawal. Many practitioners modify standard BUP induction protocols to manage these challenges, especially in non-inpatient settings.

More Related Videos

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.1K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

786

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

2.8K
Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

56.1K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

786

Area of Science:

  • Addiction Medicine
  • Pharmacology
  • Clinical Research

Background:

  • Anecdotal evidence suggests increased challenges in starting buprenorphine (BUP) treatment for individuals using illicitly manufactured fentanyl.
  • Limited empirical data exist on the prevalence and nature of these difficulties.

Purpose of the Study:

  • To determine the frequency of clinician-reported problems when initiating BUP treatment in patients using fentanyl.
  • To describe clinical strategies employed to overcome challenges in BUP treatment initiation and patient engagement.

Main Methods:

  • An online survey was administered to physicians and advanced practice clinicians.
  • The survey collected data on patient fentanyl use, BUP induction problems (precipitated/prolonged withdrawal), and clinician-reported strategies.
  • Logistic regression identified factors associated with BUP initiation problems.

Main Results:

  • Over 72% of clinicians reported problems initiating BUP in patients using fentanyl.
  • Over 61% reported patients experiencing precipitated withdrawal.
  • Clinicians with higher patient volumes, a higher proportion of patients using fentanyl, and those practicing in non-inpatient settings were more likely to report initiation problems.

Conclusions:

  • Initiating buprenorphine treatment for patients using fentanyl presents significant challenges, including precipitated withdrawal.
  • Many clinicians adapt their induction procedures and counseling in response to these difficulties.
  • Further research is needed to develop and validate alternative BUP induction strategies tailored to specific clinical settings.